Envirotainer has reported a 24 per cent year-on-year increase in the volume of life-saving medicines shipped around the world in its temperature-controlled units in 2022.
In 2021 the Envirotainer fleet moved ~600 million doses, but in 2022 this grew to ~744 million doses (272 000 pallets).
Envirotainer said it extensively expanded its production site in Rosersberg, just north of Stockholm, Sweden, in November 2022. The site is already the largest in the world in terms of output, according to Envirotainer, and the investment will allow the company to grow its current fleet of 7,500 FAA and EASA certified containers by another 1,300 in 2023.
The Envirotainer fleet covers more than 2,000 pharmaceutical trade lanes in over 100 countries and 300 airports. To enable the shipment of ever-increasing volumes of vaccines and treatments such as insulin to where they’re needed, Envirotainer said it would “continue to invest and innovate to bring new products to the market”.
Envirotainer’s chief business development officer Fredrik Linnér said: “The increase in our shipments reflects the huge need for efficient, secure and sustainable cold-chain solution for transporting sensitive pharmaceuticals We will continue to increase capacity, developing our product range and accelerating the digitalisation of the cold-chain industry.
“The need to safely transport pharmaceuticals while minimising wasted space in precious air cargo is unlikely to go away and we will be ready to help our customers move life-saving medicines where they need to be.”